Tislelizumab (TIS) + Chemotherapy (CT) vs Placebo (PBO) + CT in HER2-negative Advanced or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (GC/GEJC): RATIONALE-305 Study Minimum 3-year Survival Follow-up

Marcia Cruz Correa,[1]* Do-Youn Oh,[2] Ken Kato,[3] Josep Tabernero,[4] Yuxian Bai,[5] Jianhua Shi,[6] Keun-wook Lee,[7] Hidekazu Hirano,[8] David Spigel,[9] Lucjan Wyrwicz,[10] Roberto Pazo-Cid,[11] Antonio Cubillo Gracián,[12] Liyun Li,[13#] Yaling Xu,[14] Tao Sheng,[15] Silu Yang,[13] Rui-Hua Xu,[16] **Markus Möehler**,[17] on behalf of the RATIONALE-305 Investigators

[1]University of Puerto Rico, San Juan, Puerto Rico; [2]Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea; [3]Department of Head and Neck, Esophageal Medical Oncology and Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; [4]Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; [5]Harbin Medical University Cancer Hospital, Harbin, China; [6]Linyi Cancer Hospital, Linyi, China; [7]Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea; [8]Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; [9]Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, USA; [10]Narodowy Instytut Onkologii, Warsaw, Poland; [11]Hospital Universitario Miguel Servet, Zaragoza, Spain; [12]Hospital Universitario HM Sanchinarro, Madrid, Spain; [13]BeiGene (Beijing) Co., Ltd, Beijing, China; [14]BeiGene (Shanghai) Co., Ltd, Shanghai, China; [15]BeiGene USA, Inc., San Mateo, CA, USA; [16]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China; [17]Gastrointestinal Oncology, Johannes Gutenberg-University Clinic, Mainz, Germany. *Corresponding author. #Affiliation at the time of the study.

Poster No: 1437P presented at ESMO, Barcelona, Spain, September 13-17, 2024

Conclusions

After a minimum 3-year follow-up, tislelizumab (TIS; BGB-A317) plus chemotherapy (CT) as first-line treatment for gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC) continued to demonstrate clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and duration of response (DoR) compared with placebo (PBO) plus CT, with no new safety signals.

These long-term data further support TIS plus CT as a new first-line treatment option for advanced human epidermal growth factor receptor 2 (HER2)-negative GC/GEJC.

Background

GC/GEJC are among the most common cancer types worldwide, representing the 5th and 7th most common causes of death due to cancer for gastric and oesophageal cancers, respectively.[1] Checkpoint inhibition with anti–programmed cell death protein-1 (PD-1) inhibitors in combination with CT has shown improved survival in GC/GEJC over chemotherapy alone.[2-4]

TIS (an anti–PD-1 antibody) plus CT demonstrated significant OS benefit vs PBO plus CT as first-line therapy for advanced GC/GEJC in all randomised patients (hazard ratio [HR]=0.80; at final analysis) and in patients with programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥5% (HR=0.74; at the interim analysis) in the phase 3 RATIONALE-305 study (NCT03777657).[2] Two-year OS rates for TIS plus CT vs PBO plus CT in the RATIONALE-305 study were 32.7% vs 23.4%, respectively.[5] Here, we report efficacy and safety from RATIONALE-305 after a minimum 3-year follow-up.

Methods

- The RATIONALE-305 study is a randomised, double-blind, global phase 3 study (**Figure 1**)
- TAP score was evaluated in tumour tissue using the VENTANA PD-L1 (SP263) assay

Figure 1. Study Design



Stratification Factors:
- Regions of enrolment: China (including Taiwan) vs Japan and South Korea vs US and Europe and other regions
- PD-L1 expression (PD-L1 score ≥5% vs PD-L1 score <5%)
- Presence of peritoneal metastasis (yes vs no)
- Investigator-chosen CT (oxaliplatin + capecitabine or cisplatin + 5-fluorouracil)

[a] CT: oxaliplatin 130 mg/m^2 on day 1 + capecitabine 1000 mg/m^2 twice daily on days 1-14, Q3W; cisplatin 80 mg/m^2 on day 1 + 5-fluorouracil 800 mg/m^2/day on days 1-5, Q3W. [b] Investigator assessed per Response Evaluation Criteria In Solid Tumors v1.1. **Abbreviations:** CT, chemotherapy; DoR, duration of response; GC/GEJC, gastric or gastro-oesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; ITT, intent-to-treat; IV, intravenous; ORR, objective response rate; OS, overall survival; PBO, placebo; PD-L1, programmed death-ligand 1; PFS, progression-free survival; Q3W, once every 3 weeks; R, randomised; TAP, Tumor Area Positivity; TIS, tislelizumab.

Results

Patient Disposition

- Among 1657 patients assessed for eligibility, a total of 997 patients were randomised (TIS plus CT, n=501; PBO plus CT, n=496)
- At 3-year follow-up (minimum follow-up, 36.6 months), 23 (4.6%) patients treated with TIS plus CT and 10 (2.0%) patients treated with PBO plus CT remain on treatment

Efficacy

- Improvements in OS, PFS, and DoR with TIS plus CT vs PBO plus CT were maintained at 3-year follow-up (**Table 1**)
- In all patients, and at the prespecified PD-L1 TAP score cutoff points, OS was improved with TIS plus CT vs PBO plus CT (**Figure 2**)
- OS benefit was observed across all prespecified subgroups (**Figure 3**)
- Among the 273 (54.5%) patients treated with TIS plus CT vs 300 (60.5%) patients treated with PBO plus CT who received subsequent anticancer therapies, 258 (51.5%) vs 286 (57.7%) received chemotherapy, 156 (31.1%) vs 165 (33.3%) received targeted therapy, 65 (13.0%) vs 98 (19.8%) received immunotherapy, and 15 (3.0%) vs 19 (3.8%) received other therapies, respectively

Table 1. Efficacy Outcomes at 3-year Follow-up[a]

	TIS Plus CT n=501	PBO Plus CT n=496
Median OS, mo (95% CI)	15.0 (13.6, 16.5)	12.9 (12.1, 14.1)
HR (95% CI)[b]	0.79 (0.69, 0.90)	
OS rate at 36 mo, % (95% CI)	20.7 (17.1, 24.4)	13.4 (10.5, 16.6)
Median PFS, mo (95% CI)[c]	6.9 (5.7, 7.2)	6.2 (5.6, 6.9)
HR (95% CI)[b]	0.79 (0.68, 0.91)	
PFS rate at 36 mo, % (95% CI)	15.0 (11.6, 18.8)	7.5 (5.1, 10.5)
Confirmed ORR, % (95% CI)[c]	47.3 (42.9, 51.8)	40.5 (36.2, 45.0)
Median DoR (confirmed responders), mo (95% CI)	8.6 (7.9, 11.1)	7.2 (6.0, 8.5)
Remaining in response at 36 mo, % (95% CI)	24.5 (18.8, 30.6)	14.4 (9.3, 20.5)

[a] ITT analysis set. [b] Stratified by region (East Asia vs rest of world), PD-L1 expression, and presence of peritoneal metastasis. [c] Investigator evaluated. **Abbreviations:** CI, confidence interval; CT, chemotherapy; DoR, duration of response; HR, hazard ratio; ITT, intent-to-treat; mo, months; ORR, objective response rate; OS, overall survival; PBO, placebo; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TIS, tislelizumab.

Figure 2. Kaplan-Meier Curves of OS at 3-year Follow-up



All Patients[a]	TIS Plus CT (n=501)	PBO Plus CT (n=496)
Events	396	430
Median OS, mo (95% CI)	15.0 (13.6, 16.5)	12.9 (12.1, 14.1)
HR (95% CI)	0.79 (0.69, 0.90)	



PD-L1 TAP Score ≥5%	TIS Plus CT (n=274)	PBO Plus CT (n=272)
Events	209	233
Median OS, mo (95% CI)	16.4 (13.6, 19.1)	12.8 (12.0, 14.5)
HR (95% CI)	0.71 (0.59, 0.86)	

HR values are stratified. [a] ITT analysis set. **Abbreviations:** CI, confidence interval; CT, chemotherapy; HR, hazard ratio; ITT, intent-to-treat; mo, months; OS, overall survival; PBO, placebo; PD-L1, programmed death-ligand 1; TAP, Tumor Area Positivity; TIS, tislelizumab.

Figure 3. Forest Plot of OS by Subgroup at 3-year Follow-up[a]



Subgroup	Events/Total TIS Plus CT	Events/Total PBO Plus CT	HR for Death (95% CI)	HR (95% CI)
Age				
<65 years	271/340	279/313		0.79 (0.67, 0.93)
≥65 years	125/161	151/183		0.80 (0.63, 1.01)
Sex				
Male	269/346	297/346		0.79 (0.67, 0.93)
Female	127/155	133/150		0.79 (0.62, 1.01)
Region[b]				
East Asia	288/376	320/372		0.79 (0.68, 0.93)
Rest of world	108/125	110/124		0.73 (0.56, 0.96)
ECOG performance status				
0	139/169	134/154		0.77 (0.61, 0.98)
1	257/332	296/342		0.80 (0.67, 0.94)
PD-L1 expression				
PD-L1 TAP score <5%	187/227	197/224		0.89 (0.73, 1.09)
PD-L1 TAP score ≥5%	209/274	233/272		0.72 (0.60, 0.87)
Peritoneal metastasis				
Yes	184/220	196/214		0.78 (0.64, 0.96)
No	212/281	234/282		0.79 (0.65, 0.95)
Liver metastasis				
Yes	150/190	165/188		0.77 (0.62, 0.96)
No	246/311	265/308		0.80 (0.67, 0.95)

HR values are unstratified. [a] ITT analysis set. [b] East Asia includes Japan, Korea, China, and Taiwan. Rest of world includes the US, Russia, France, Spain, Italy, UK, Poland, and Turkey. **Abbreviations:** CI, confidence interval; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; mo, months; OS, overall survival; PBO, placebo; PD-L1, programmed death-ligand 1; TAP, Tumor Area Positivity; TIS, tislelizumab.

Safety

- Safety was maintained at 3-year follow-up (**Table 2**)
- The numbers of treatment-related adverse events (TRAEs), grade ≥3 TRAEs, and treatment-emergent adverse events leading to dose modification were similar in both arms
- The most common grade ≥3 TRAEs were neutrophil and platelet count decreased

Table 2. Safety at 3-year Follow-up[a]

	TIS Plus CT n=498	PBO Plus CT n=494
Patients with ≥1 TRAE for any treatment component	483 (97.0)	476 (96.4)
Grade ≥3 TRAEs	269 (54.0)	246 (49.8)
Occurring at ≥5% incidence		
Neutrophil count decreased	59 (11.8)	57 (11.5)
Platelet count decreased	56 (11.2)	57 (11.5)
Neutropenia	33 (6.6)	34 (6.9)
Anaemia	25 (5.0)	37 (7.5)
Serious TRAEs for any treatment component	113 (22.7)	72 (14.6)
TRAEs leading to any treatment discontinuation	83 (16.7)	40 (8.1)
TEAEs leading to dose modification of any treatment component	381 (76.5)	375 (75.9)
TRAEs leading to death[b]	6 (1.2)[c]	2 (0.4)[d]

[a] Patients with ≥2 events for the same preferred term were counted only once for the preferred term. [b] Excludes death due to disease progression. [c] Death (n=4), colitis (n=1), sepsis (n=1), subdural haematoma (n=1). [d] Pneumonia (n=2). **Abbreviations:** CT, chemotherapy; PBO, placebo; TEAE, treatment-emergent adverse event; TIS, tislelizumab; TRAE, treatment-related adverse event.

References

1. Bray F, et al. *CA Cancer J Clin*. 2024;74(3):229-263.
2. Qiu M, et al. *BMJ*. 2024;385:e078876.
3. Janjigian YY, et al. *J Clin Oncol*. 2024;42(17):2012-2020.
4. Rha SY, et al. *Lancet Oncol*. 2023;24(11):1181-1195.
5. Smith D, et al. Presented at JFHOD 2024; Abstract P.005.

Acknowledgements

We would like to thank the investigators, the site support staff, and especially the patients for participating in this study.
This study was sponsored by BeiGene. Medical writing support was provided by Lauren D. Van Wassenhove, PhD, of Parexel, with funding provided by BeiGene.

Disclosures

MM reports serving in a consultancy/advisory role for Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Dragonfly Lilly, Merck Serono, MSD, Novartis, Pfizer, Roche, Servier Laboratories, and Taiho Pharmaceutical; receiving honoraria from Amgen, Astellas, AstraZeneca/MedImmune, BMS, Daiichi Sankyo, Falk Foundation, Merck Serono, MSD Oncology, Nordic Pharma, Pierre Fabre, Roche/Genentech, Sanofi, Servier Laboratories, and Transcenta Holding; receiving grant/research funding from Amgen, Leap Therapeutics, Merck Serono, and MSD; and receiving other remuneration from Amgen, ASCO, Bayer, BeiGene, EORTC, ESMO, German Cancer Society, Merck Serono, MSD, and Roche.